Indoco Remedies Limited — Important, 21-01-2025: Financial Result Updates

**Consolidated Financial Summary for Indoco Remedies**

Consolidated income from operations for the quarter ended December 31, 2024, stood at ₹ 41,055 million, reflecting a decrease of approximately 10.2% compared to ₹ 45,942 million in the same quarter last year. The decline is attributed to challenges within the Export Formulation Business, primarily due to supply constraints from sites undergoing planned shutdowns.

Net loss for the quarter amounted to ₹ 2,840 million, significantly worsening from a profit of ₹ 1,556 million year-on-year. This downturn was influenced by increased operational costs, primarily in materials consumed, which rose to ₹ 10,991 million compared to ₹ 12,930 million the previous year, alongside higher finance costs.

Earnings per share (EPS) for the quarter were reported at ₹ (3.08), contrasting sharply with earnings of ₹ 1.69 in the previous year, emphasizing the company's current profitability challenges.

Total expenses for the quarter reached ₹ 44,335 million, leading to a loss before tax of ₹ (3,096) million. The operational efficiency issues and the required enhancements at manufacturing sites have negatively impacted profitability, indicating a need for strategic focus on cost management and resolving supply chain constraints.

Investors may consider holding their positions pending further developments in the company’s operational recovery and growth strategy.